European Patent Office

T 0569/21 (Combination treatment for cystic fibrosis / VERTEX) of 07.12.2023

European Case Law Identifier
ECLI:EP:BA:2023:T056921.20231207
Date of decision
7 December 2023
Case number
T 0569/21
Petition for review of
-
Application number
15721912.2
Language of proceedings
English
Distribution
No distribution (D)
OJ versions
No OJ links found
Other decisions for this case
-
Abstracts for this decision
-
Application title
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES
Applicant name
Vertex Pharmaceuticals Incorporated
Opponent name
Generics (U.K.) Limited
Board
3.3.04
Headnote
-
Relevant legal provisions
European Patent Convention Art 123(2)European Patent Convention Art 123(3)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 83Rules of procedure of the Boards of Appeal 2020 Art 012(3)Rules of procedure of the Boards of Appeal 2020 Art 012(5)Rules of procedure of the Boards of Appeal 2020 Art 013(2)
Keywords
Main request - amendments - added subject-matter (no)
Main request - sufficiency of disclosure (yes)
Main request - novelty (yes)
Inventive step - (yes)
Inventive step - unexpected improvement shown
Objection of lack of inventive step - not substantiated - admitted (no)
Late-filed request - circumstances of appeal case justify admittance (yes)
Catchword
-
Citing cases
-

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the opposition division with the order to maintain the patent based on the following documents:

claims 1 to 21 of the main request submitted during the oral proceedings as new auxiliary request 1; the description and drawings possibly to be adapted thereto.